Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Jana Dawson"'
Autor:
Christopher L. Cubitt, Jiliana Menth, Jana Dawson, Gary V. Martinez, Parastou Foroutan, David L. Morse, Marilyn M. Bui, G. Douglas Letson, Daniel M. Sullivan, Damon R. Reed
Publikováno v:
Sarcoma, Vol 2013 (2013)
For patients with sarcoma, metastatic disease remains very difficult to cure, and outcomes remain less than optimal. Treatment options have not largely changed, although some promising gains have been made with single agents in specific subtypes with
Externí odkaz:
https://doaj.org/article/1ee65d14d9e0473fbe8be9ef7aa461e1
Autor:
Pamela N. Munster, Daniel M. Sullivan, Anthony Neuger, Richard Lush, Frederick A. Hausheer, Sem Bastien, Douglas Marchion, Elona Bicaku, Ronald C. DeConti, Jana Dawson, Adil I. Daud
Supplementary Data from Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d9697e5388a426a347a91ff8cd34505
https://doi.org/10.1158/1078-0432.22440090
https://doi.org/10.1158/1078-0432.22440090
Autor:
Steven Grant, Daniel Sullivan, John D. Roberts, Domenico Coppola, William D. Figg, L. Austin Doyle, A. Dimitrios Colevas, Kevin T. Hogan, Heidi Sankala, Martha Wellons, Caryn Weir-Wiggins, Ellen Shrader, Mary Beth Tombes, Connie Honeycutt, Loveleen Kang, Jana Dawson, Cody J. Peer, Wen Wan, Viswanathan Ramakrishnan, Robert K. Stuart, G. David Roodman, Rachid C. Baz, Prithviraj Bose, E. Brent Perkins, Maciej Kmieciak, Beata Holkova
Purpose: This phase I study was conducted to determine the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) for the combination of bortezomib and alvocidib in patients with B-cell malignancies (multiple myeloma, indolent lymphoma, Wald
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1977bb1d8752a76f5c5c3a66840e9b56
https://doi.org/10.1158/1078-0432.c.6523721
https://doi.org/10.1158/1078-0432.c.6523721
Autor:
Steven Grant, Daniel Sullivan, John D. Roberts, Domenico Coppola, William D. Figg, L. Austin Doyle, A. Dimitrios Colevas, Kevin T. Hogan, Heidi Sankala, Martha Wellons, Caryn Weir-Wiggins, Ellen Shrader, Mary Beth Tombes, Connie Honeycutt, Loveleen Kang, Jana Dawson, Cody J. Peer, Wen Wan, Viswanathan Ramakrishnan, Robert K. Stuart, G. David Roodman, Rachid C. Baz, Prithviraj Bose, E. Brent Perkins, Maciej Kmieciak, Beata Holkova
Supplementary Materials. Supplemental Table 1. C1D1 alvocidib pharmacokinetics by dose Supplemental Figure 1. Sample alvocidib concentration-time profile. Samples were obtained pre-infusion, immediately following infusion, and at 1, 2, 4, 8, 12, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bd0c9ee46edd870313723694cee3dd6
https://doi.org/10.1158/1078-0432.22457846
https://doi.org/10.1158/1078-0432.22457846
Autor:
Steven Grant, John D. Roberts, Daniel M. Sullivan, John Wright, Austin Doyle, Sarah Kolla, William D. Figg, Cody Peer, Robert K. Stuart, Jana Dawson, Loveleen Kang, Domenico Coppola, G. David Roodman, Kevin T. Hogan, Martha D. Wellons, Neha Talreja, Ellen Shrader, Mary Beth Tombes, Viswanathan Ramakrishnan, E. Brent Perkins, Beata Holkova
Supplementary Figures S1-S2; Supplementary Tables S1-S2.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d81f3e9a58f242d78b23b30cad7b712
https://doi.org/10.1158/1078-0432.22441095.v1
https://doi.org/10.1158/1078-0432.22441095.v1
Autor:
Pamela N. Munster, Daniel M. Sullivan, Anthony Neuger, Richard Lush, Frederick A. Hausheer, Sem Bastien, Douglas Marchion, Elona Bicaku, Ronald C. DeConti, Jana Dawson, Adil I. Daud
Purpose: The novel topoisomerase I inhibitor karenitecin (KTN) shows activity against melanoma. We examined whether histone deacetylase inhibition could potentiate the DNA strand cleavage, cytotoxicity as well as the clinical toxicity, and efficacy o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6efe0e46b300c1561e799201cc208254
https://doi.org/10.1158/1078-0432.c.6517464.v1
https://doi.org/10.1158/1078-0432.c.6517464.v1
Autor:
Joel G. Turner, Jana Dawson, Alexis Bauer, Juan Gomez, Erkan Baloglu, Yosef Landesman, Daniel M. Sullivan
Publikováno v:
Cancer Research. 79:285-285
Introduction In the past decade, response and survival rates in multiple myeloma (MM) patients have been greatly increased by newer therapies. Nevertheless, most patients with MM eventually die from relapsed/refractory disease. Previous studies in ou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fbe63cde835e54d90b63ead708c03f74
https://doi.org/10.1158/1538-7445.am2019-285
https://doi.org/10.1158/1538-7445.am2019-285